Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to -$22.2 million.

  • Standard Biotools' Cash from Operations rose 2033.44% to -$22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.2 million, marking a year-over-year increase of 3920.64%. This contributed to the annual value of -$143.5 million for FY2024, which is 23140.2% down from last year.
  • Per Standard Biotools' latest filing, its Cash from Operations stood at -$22.2 million for Q3 2025, which was up 2033.44% from -$20.7 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Cash from Operations registered a high of -$7.0 million during Q4 2021, and its lowest value of -$62.5 million during Q1 2024.
  • Moreover, its 5-year median value for Cash from Operations was -$15.6 million (2022), whereas its average is -$20.7 million.
  • As far as peak fluctuations go, Standard Biotools' Cash from Operations skyrocketed by 6889.09% in 2023, and later crashed by 63631.11% in 2024.
  • Quarter analysis of 5 years shows Standard Biotools' Cash from Operations stood at -$7.0 million in 2021, then tumbled by 173.94% to -$19.2 million in 2022, then increased by 26.69% to -$14.1 million in 2023, then increased by 0.01% to -$14.1 million in 2024, then crashed by 57.92% to -$22.2 million in 2025.
  • Its Cash from Operations was -$22.2 million in Q3 2025, compared to -$20.7 million in Q2 2025 and -$30.3 million in Q1 2025.